Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels

Detalhes bibliográficos
Principais autores:	Mihaylova, B, Briggs, A, Hlatky, M, Armitage, J, Parish, S, Gray, A, Collins, R, Study, HP
Formato:	Journal article
Publicado em:	2009

Registros relacionados

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
por: Mihaylova, B, et al.
Publicado em: (2005)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
por: Mihaylova, B, et al.
Publicado em: (2005)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
por: Mihaylova, B, et al.
Publicado em: (2006)

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
por: Mihaylova, B, et al.
Publicado em: (2024)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
por: Kent, S, et al.
Publicado em: (2016)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
por: Hopewell, J, et al.
Publicado em: (2009)

Statins for people at low risk of cardiovascular disease reply
por: Mihaylova, B, et al.
Publicado em: (2012)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
por: Mihaylova, B, et al.
Publicado em: (2012)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
por: Hopewell, J, et al.
Publicado em: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
por: Hopewell, J, et al.
Publicado em: (2011)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
por: Hopewell, J, et al.
Publicado em: (2011)

Economic evaluation of the Heart Protection Study
por: Briggs, A, et al.
Publicado em: (2003)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
por: Mihaylova, B, et al.
Publicado em: (2019)

Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the United Kingdom and United States
por: Lui, JNM, et al.
Publicado em: (2023)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
por: Collins, R, et al.
Publicado em: (2004)

Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials
por: Cholesterol Treatment Trialists' Collaboration, et al.
Publicado em: (2019)

Misrepresentation of statin safety evidence.
por: Armitage, J, et al.
Publicado em: (2014)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
por: Hopewell, J, et al.
Publicado em: (2010)

Impact of New Cardiovascular Events on Quality of Life and Hospital Costs in People With Cardiovascular Disease in the United Kingdom and United States
por: Juliana Nga Man Lui, et al.
Publicado em: (2023-10-01)

Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
por: Armstrong SO, et al.
Publicado em: (2019-08-01)

Statin use for cardiovascular disease prevention: perceptions among people living with HIV in the United States
por: Adedotun Ogunbajo, et al.
Publicado em: (2024-04-01)

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant datasets
por: Mihaylova, B, et al.
Publicado em: (2024)

Hospital costs associated with adverse events in people with diabetes in the UK
por: Keng, MJ, et al.
Publicado em: (2022)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
por: Link, E, et al.
Publicado em: (2008)

Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States
por: Mitchell Aaron P, et al.
Publicado em: (2012-07-01)

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study
por: Mihaylova, B, et al.
Publicado em: (2024)

Lessons from the controversy over statins - Authors' reply.
por: Armitage, J, et al.
Publicado em: (2016)

Safety and efficacy of statins - Authors' reply
por: Collins, R, et al.
Publicado em: (2017)

The safety of statins in clinical practice.
por: Armitage, J
Publicado em: (2007)

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
por: Borislava Mihaylova, et al.
Publicado em: (2024-12-01)

Statins and the progression of age-related macular degeneration in the United States.
por: Cassie A Ludwig, et al.
Publicado em: (2021-01-01)

Statins and the progression of age-related macular degeneration in the United States
por: Cassie A. Ludwig, et al.
Publicado em: (2021-01-01)

Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.
por: Margaritis, M, et al.
Publicado em: (2014)

Familial Resemblance in Low‐Density Lipoprotein Cholesterol Response to Statins in the Danish Population
por: Giulia Corn, et al.
Publicado em: (2022-06-01)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
por: Mangravite, L, et al.
Publicado em: (2013)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
por: Mangravite, L, et al.
Publicado em: (2013)

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
por: Kearney, P, et al.
Publicado em: (2008)

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyResearch in context
por: Borislava Mihaylova, et al.
Publicado em: (2024-05-01)

Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
por: Wu, R, et al.
Publicado em: (2023)

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
por: Thalmann, I, et al.
Publicado em: (2022)